Engineered retroviral virus-like particles for receptor targeting

Area of Science:

• Biotechnology
• Molecular Biology
• Virology

Background:

• Retroviral gag proteins self-assemble into virus-like particles (VLPs), incorporating nucleic acids.
• Mason-Pfizer monkey virus (M-PMV) capsid-nucleocapsid (CA-NC) subunits can form non-enveloped VLPs in vitro.
• Targeted delivery of therapeutic molecules remains a challenge in gene therapy.

Purpose of the Study:

• To engineer M-PMV VLPs for targeted delivery of small interfering RNA (siRNA).
• To create a safe and efficient viral vector system for intracellular delivery.

Main Methods:

• Generated non-enveloped M-PMV VLPs from self-assembling CA-NC subunits in an in vitro system.
• Modified VLPs by N-terminally extending CA-NC with oligopeptides for cell surface targeting.
• Incorporated siRNA into forming VLPs and demonstrated delivery into target cell cytosol.

Main Results:

• Engineered M-PMV VLPs specifically interacted with cells expressing prostate-specific membrane antigen.
• Successfully delivered functional siRNA into the cytosol of target cells.
• The M-PMV VLP system demonstrated low risk of pathology due to the absence of viral coding sequences.

Conclusions:

• N-terminally modified M-PMV VLPs serve as a promising targeted delivery vector for siRNA.
• This cell-free VLP system offers a safer alternative to traditional viral vectors for gene therapy applications.